Inflammatory Bowel Disease

Discussing the latest advances in Crohn’s disease and ulcerative colitis

Clinical Trials

May 11th, 2016

CCFA to Study Impact of Specific Diets on Crohn’s Disease

By Kanaaz Pereira kanaazpe

One of the first questions that people diagnosed with inflammatory bowel disease (IBD) have is, “What can I eat, and will changing my diet help with the symptoms or even cure my disease?”  The Crohn’s & Colitis Foundation of America (CCFA) has been given $2.5 million to investigate the value of a carbohydrate-rich diet and a Mediterranean-style diet in preventing relapse in […]

View full entry

Tags: Crohn's & Colitis Foundation of America (CCFA), dietary changes, Food and Crohn's Exacerbation Study (FACES), IBD, Sunanda Kane


September 13th, 2015

No Association Between Isotretinoin Exposure and IBD

By Kanaaz Pereira kanaazpe

The association between the use of Isotretinoin, a synthetic vitamin A derivate, and the risk of inflammatory bowel disease (IBD), remains a controversial issue, according to a study published in JAMA Dermatology. Dr. Joseph Murray, M.D., and colleagues conducted a single-center study of about 1,000 people in Olmsted County, Minnesota, and separated them into two groups.The […]

View full entry

Tags: acne, IBD, Isotretinoin, JAMA Dermatology, Joseph Murray


July 3rd, 2015

Genome Sequencing Plays Increasing Role in Pediatric IBD

By Kanaaz Pereira kanaazpe

Over the past two decades, researchers have been better able to understand the role of genetics in patients with inflammatory bowel disease (IBD). At Mayo Clinic, a unique collaboration between pediatric gastroenterology and the Center for Individualized Medicine (CIM) offers young patients the opportunity for deep sequencing of DNA, and in most cases exome sequencing to try […]

View full entry

Tags: Center for Individualized Medicine, Digestive Diseases Update, genetics, IBD, Michael C. Stephens


October 15th, 2014

Proactive Monitoring

By Margaret Shepard, Communications Specialist Margaret_Marie

Edward Loftus Jr., M. D., discusses a recently published article in Inflammatory Bowel Diseases that looks at proactive Infliximab drug monitoring in patients. Infliximab treats Crohn’s diseases and more recently, ulcerative colitis. The recently published paper looks at proactive monitoring, instead of reactive monitoring which physicians have been doing. A physician at Bethel Decan Medical Center in […]

View full entry

Tags: Edward Loftus, IBD, monitoring


October 9th, 2014

Crohn’s Disease and Remission with Vedolizumab

By Margaret Shepard, Communications Specialist Margaret_Marie

Edward Loftus Jr., M. D., discusses a recent article published in Gastroenterology looking at how well vedolizumab works with Crohn’s disease patients who have already been on an anti-TNF agent.   The study specifically examined the question of how well vedolizumab in patients with Crohn’s disease who have already been on a different type of […]

View full entry

Tags: Crohn's disease, Edward Loftus, Gastroenterology, Vedolizumab


August 8th, 2014

Mesalamine Dose May Lower Marker of Bowel Inflammation

By Margaret Shepard, Communications Specialist Margaret_Marie

Edward Loftus Jr., M. D., discusses a recent article published in Clinical Gastroenterology and Hepatology looking at the ability of a drug to drive down calprotectin, a marker of bowel inflammation, in ulcerative colitis patients. This protein can be measured in stool, which gives physicians a proxy of how much inflammation is occurring in the bowel. […]

View full entry

Tags: bowel inflammation, Clinical Gastroenterology and Hepatology, Edward Loftus, mesalamine, ulcerative colitis


July 24th, 2014

Anti-TNF Therapy and Remission in Pediatric Crohn’s Disease

By Margaret Shepard, Communications Specialist Margaret_Marie

Jeanne Tung, M.D., discusses a recently published article in Pediatrics about anti-TNF drug therapy and remission rates in pediatric Crohn’s disease. This study was conducting using the ImproveCareNow database.   The ImproveCareNow registry was started in 2006 with the idea of improving care in pediatric GI centers. Mayo Clinic joined ImproveCareNow in 2011 and there are now […]

View full entry

Tags: Crohn's disease, drug therapy, Improve Care Now, Jeanne Tung, pediatric Crohn's disease, pediatrics, remission


July 10th, 2014

Cancer Risk Greater in Crohn’s Disease Patients Treated with Combination Drug Therapy

By Margaret Shepard, Communications Specialist Margaret_Marie

John Kisiel, M.D., discusses a recently published article in Gastroenterology about the combination therapy of adalimumab and immunomodulators and the risk for cancer in patients with Crohn’s disease.   Recent studies have shown greater benefit when combining anti-TNF drugs with thiopurine drugs. Doctors have known for awhile that certain thiopurine drugs raise the risk of certain […]

View full entry

Tags: adalimumab, AGA, cancer, Crohn's disease, Gastroenterology, John Kisiel, nonmelanoma skin cancer


June 19th, 2014

Clinical Trials and IBD

By Margaret Shepard, Communications Specialist Margaret_Marie

Have you ever thought about joining a clinical trial? Many patients have benefited from participating in clinical trials. Edward Loftus Jr., M. D., discusses the pros and cons of entering a clinical trial for new drugs for patients with inflammatory bowel disease (IBD). What are the pros? Might get access to a drug years before […]

View full entry

Tags: clinical trials, Edward Loftus, IBD


June 5th, 2014

Etrolizumab and IBD

By Margaret Shepard, Communications Specialist Margaret_Marie

Edward Loftus Jr., M. D., discusses a recently published article in The Lancet about the phase two trial of Etrolizumab, which is a drug for patients with moderate to severe ulcerative colitis.   The molecule of this drug is an antibody directed at a substance called beta seven integrin. Integrins are molecules that act with […]

View full entry

Tags: Edward Loftus, Etrolizumab, FDA, IBD, The Lancet, ulcerative colitis


Contact Us · Privacy Policy